liver failure
Conditions
Interventions
Group A:heparin anticoagulation
Group B:regional citrate anticoagulation
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with HBV-ACLF who received plasma adsorption followed by PE for the first session of ALSS therapy were enrolled. The diagnosis of HBV-ACLF was mainly based on the following criteria: 1. pre-existing chronic hepatitis B virus infection; 2. progressive hyperbilirubinemia, defined as a > 50% increase in bilirubin or up to a level of > 171umol/L within 4 weeks; 3. prothrombin time activity (PTA)=40% or international normalized ratio (INR)=1.5.
Exclusion criteria
Exclusion criteria: Patients whose aged less than 18 years or more than 70 years were excluded. Patients were excluded if they had the following diseases: drug-induced liver injury, immune-related liver disease, alcoholic liver disease, and hyperthyroidism, and patients who were pregnant were also excluded. In addition, patients with HBV-ACLF were excluded if they were complicated with other viral infections (including hepatitis A, C, D or E virus, cytomegalovirus, herpes simplex virus, or human immunodeficiency virus), or had evidence of chronic heart, pulmonary, or kidney diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Citrate accumulation;Acid-base disorders;Completion rates; | — |
Countries
China
Contacts
Public ContactLang Bai
West China Hospital, Sichuan University
Outcome results
None listed